Kazushi Uneda, Tetsuhiro Yoshino, Hidenori Ito, S. Imoto, Tatsuya Nogami
We aimed to elucidate the present clinical situation, future challenges, and potential need for diagnostic support software in Kampo medicine.We conducted an online survey (comprising 28 questions) of Japanese physicians from the 23 to 24 January 2024 via MedPeer. The participants' responses were stratified according to their age distribution.We evaluated data for 652 respondents. The most common respondent age groups were those in their 30s and 40s. The most common specialty of respondents was internal medicine (43.7%). Only 33.7% of respondents had received education on Kampo medicine at university. Most respondents (90.0%) were not licensed as certified physicians or members of the Japan Society for Oriental Medicine. Most respondents (86.7%) currently prescribed Kampo formulas (current users); only 3.8% had no experience in prescribing Kampo formulas. The conditions for which Kampo formulas were frequently prescribed were muscle cramps, constipation, medically unexplained symptoms/menopausal syndrome, appetite loss/malnutrition, and fatigue. However, 48.3% of current users did not use traditional Kampo patterns (sho). The most frequent issues reported by respondents were the lack of scientific evidence and standardization of diagnostic methods in Kampo medicine. Respondents indicated the need for postgraduate education and implementation of diagnostic support software for using Kampo patterns by non‐specialists in Kampo medicine.There was a discrepancy between the high frequency of Kampo formula prescriptions and the low use of traditional Kampo patterns in Japan. Diagnostic support software is likely to become a useful method of improving appropriate Kampo formula prescriptions by non‐specialists.
{"title":"Current situation and future issues with Kampo medicine: A survey of Japanese physicians","authors":"Kazushi Uneda, Tetsuhiro Yoshino, Hidenori Ito, S. Imoto, Tatsuya Nogami","doi":"10.1002/tkm2.1418","DOIUrl":"https://doi.org/10.1002/tkm2.1418","url":null,"abstract":"We aimed to elucidate the present clinical situation, future challenges, and potential need for diagnostic support software in Kampo medicine.We conducted an online survey (comprising 28 questions) of Japanese physicians from the 23 to 24 January 2024 via MedPeer. The participants' responses were stratified according to their age distribution.We evaluated data for 652 respondents. The most common respondent age groups were those in their 30s and 40s. The most common specialty of respondents was internal medicine (43.7%). Only 33.7% of respondents had received education on Kampo medicine at university. Most respondents (90.0%) were not licensed as certified physicians or members of the Japan Society for Oriental Medicine. Most respondents (86.7%) currently prescribed Kampo formulas (current users); only 3.8% had no experience in prescribing Kampo formulas. The conditions for which Kampo formulas were frequently prescribed were muscle cramps, constipation, medically unexplained symptoms/menopausal syndrome, appetite loss/malnutrition, and fatigue. However, 48.3% of current users did not use traditional Kampo patterns (sho). The most frequent issues reported by respondents were the lack of scientific evidence and standardization of diagnostic methods in Kampo medicine. Respondents indicated the need for postgraduate education and implementation of diagnostic support software for using Kampo patterns by non‐specialists in Kampo medicine.There was a discrepancy between the high frequency of Kampo formula prescriptions and the low use of traditional Kampo patterns in Japan. Diagnostic support software is likely to become a useful method of improving appropriate Kampo formula prescriptions by non‐specialists.","PeriodicalId":507365,"journal":{"name":"Traditional & Kampo Medicine","volume":"28 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141810003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dariush Mehboodi, Abbas Shahedi, Mohammadreza Namavar, Fatemeh Zakizadeh, Arezoo Teymoori
Global cerebral ischemia (GCI) is characterized by the hindrance of blood flow to the brain due to obstruction in the carotid arteries. In this study, the neuroprotective effects of berberine chloride (BBR) and cinnamaldehyde (CA) against GCI in male Wistar rats were investigated, and their efficacy was compared.Twenty‐four rats were randomly assigned to four groups: Sham, GCI, GCI + BBR, and GCI + CA. 100 mg/kg of BBR and CA were administered five minutes and six hours after inducing GCI by occluding two common carotids for 20 minutes.The findings showed that both compounds mitigated GCI‐induced damage to the hippocampus and its subfields, and CA demonstrated better neuroprotective efficacy than BBR. These results was also supported by behavioural tests, which revealed better memory function in GCI + CA compared to GCI + BBR.The study showed the neuroprotective impact of CA and BBR against GCI, and CA emerged as a more effective therapeutic agent against GCI‐induced damage. Further research is necessary to uncover the specific mechanisms behind these differences.
{"title":"Stereological and behavioural analysis reveals the better neuroprotective effect of cinnamaldehyde than berberine chloride in a rat model of global cerebral ischemia","authors":"Dariush Mehboodi, Abbas Shahedi, Mohammadreza Namavar, Fatemeh Zakizadeh, Arezoo Teymoori","doi":"10.1002/tkm2.1413","DOIUrl":"https://doi.org/10.1002/tkm2.1413","url":null,"abstract":"Global cerebral ischemia (GCI) is characterized by the hindrance of blood flow to the brain due to obstruction in the carotid arteries. In this study, the neuroprotective effects of berberine chloride (BBR) and cinnamaldehyde (CA) against GCI in male Wistar rats were investigated, and their efficacy was compared.Twenty‐four rats were randomly assigned to four groups: Sham, GCI, GCI + BBR, and GCI + CA. 100 mg/kg of BBR and CA were administered five minutes and six hours after inducing GCI by occluding two common carotids for 20 minutes.The findings showed that both compounds mitigated GCI‐induced damage to the hippocampus and its subfields, and CA demonstrated better neuroprotective efficacy than BBR. These results was also supported by behavioural tests, which revealed better memory function in GCI + CA compared to GCI + BBR.The study showed the neuroprotective impact of CA and BBR against GCI, and CA emerged as a more effective therapeutic agent against GCI‐induced damage. Further research is necessary to uncover the specific mechanisms behind these differences.","PeriodicalId":507365,"journal":{"name":"Traditional & Kampo Medicine","volume":" 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141371089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The “Yasui Classification” categorizes the indication for Kampo medicine into four main types in the medical field where standard treatment of Western medicine exists regardless of the school of Kampo medicine. We aimed to elucidate how Kampo case reports are presented from the viewpoint of the Yasui Classification.Using the general presentations at the 69th Japan Society for Oriental Medicine (JSOM) Academic Meeting held in Osaka in June 2018, the contents of each abstract were analyzed with the Yasui Classification.There were 289 abstracts. The numbers of included abstracts was 140 (48.4%), and their breakdown was as follows: Type 1: 97, Type 2: 27, Type 3: 12, and Type 4: 4. Therefore, Kampo monotherapy yielded the greatest number of presentations where Western medicine‐refractory cases were treated with Kampo medicine. In Type 2, which is the combination of Kampo and Western medicines, there were various applications of Kampo medicine in clinical fields such as pain control, respiratory, cardiovascular, and psychiatric subspecialties. Furthermore, in Type 3, which is also the combination of Kampo and Western medicines, 7 of 12 presentations were related to the alleviation of the side effects of cancer therapy.Kampo monotherapy is most popularly reported at the Congress of JSOM in various fields of medicine, whereas the concurrent use of Kampo and Western medicines is also reported in a variety of clinical subspecialties. A new horizon of clinical significance for Kampo medicine will be opened with the Yasui Classification.
{"title":"Analysis of Kampo case reports from the viewpoint of “Yasui Classification”","authors":"Y. Motoo, Hiromichi Yasui","doi":"10.1002/tkm2.1398","DOIUrl":"https://doi.org/10.1002/tkm2.1398","url":null,"abstract":"The “Yasui Classification” categorizes the indication for Kampo medicine into four main types in the medical field where standard treatment of Western medicine exists regardless of the school of Kampo medicine. We aimed to elucidate how Kampo case reports are presented from the viewpoint of the Yasui Classification.Using the general presentations at the 69th Japan Society for Oriental Medicine (JSOM) Academic Meeting held in Osaka in June 2018, the contents of each abstract were analyzed with the Yasui Classification.There were 289 abstracts. The numbers of included abstracts was 140 (48.4%), and their breakdown was as follows: Type 1: 97, Type 2: 27, Type 3: 12, and Type 4: 4. Therefore, Kampo monotherapy yielded the greatest number of presentations where Western medicine‐refractory cases were treated with Kampo medicine. In Type 2, which is the combination of Kampo and Western medicines, there were various applications of Kampo medicine in clinical fields such as pain control, respiratory, cardiovascular, and psychiatric subspecialties. Furthermore, in Type 3, which is also the combination of Kampo and Western medicines, 7 of 12 presentations were related to the alleviation of the side effects of cancer therapy.Kampo monotherapy is most popularly reported at the Congress of JSOM in various fields of medicine, whereas the concurrent use of Kampo and Western medicines is also reported in a variety of clinical subspecialties. A new horizon of clinical significance for Kampo medicine will be opened with the Yasui Classification.","PeriodicalId":507365,"journal":{"name":"Traditional & Kampo Medicine","volume":"66 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139801766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The “Yasui Classification” categorizes the indication for Kampo medicine into four main types in the medical field where standard treatment of Western medicine exists regardless of the school of Kampo medicine. We aimed to elucidate how Kampo case reports are presented from the viewpoint of the Yasui Classification.Using the general presentations at the 69th Japan Society for Oriental Medicine (JSOM) Academic Meeting held in Osaka in June 2018, the contents of each abstract were analyzed with the Yasui Classification.There were 289 abstracts. The numbers of included abstracts was 140 (48.4%), and their breakdown was as follows: Type 1: 97, Type 2: 27, Type 3: 12, and Type 4: 4. Therefore, Kampo monotherapy yielded the greatest number of presentations where Western medicine‐refractory cases were treated with Kampo medicine. In Type 2, which is the combination of Kampo and Western medicines, there were various applications of Kampo medicine in clinical fields such as pain control, respiratory, cardiovascular, and psychiatric subspecialties. Furthermore, in Type 3, which is also the combination of Kampo and Western medicines, 7 of 12 presentations were related to the alleviation of the side effects of cancer therapy.Kampo monotherapy is most popularly reported at the Congress of JSOM in various fields of medicine, whereas the concurrent use of Kampo and Western medicines is also reported in a variety of clinical subspecialties. A new horizon of clinical significance for Kampo medicine will be opened with the Yasui Classification.
{"title":"Analysis of Kampo case reports from the viewpoint of “Yasui Classification”","authors":"Y. Motoo, Hiromichi Yasui","doi":"10.1002/tkm2.1398","DOIUrl":"https://doi.org/10.1002/tkm2.1398","url":null,"abstract":"The “Yasui Classification” categorizes the indication for Kampo medicine into four main types in the medical field where standard treatment of Western medicine exists regardless of the school of Kampo medicine. We aimed to elucidate how Kampo case reports are presented from the viewpoint of the Yasui Classification.Using the general presentations at the 69th Japan Society for Oriental Medicine (JSOM) Academic Meeting held in Osaka in June 2018, the contents of each abstract were analyzed with the Yasui Classification.There were 289 abstracts. The numbers of included abstracts was 140 (48.4%), and their breakdown was as follows: Type 1: 97, Type 2: 27, Type 3: 12, and Type 4: 4. Therefore, Kampo monotherapy yielded the greatest number of presentations where Western medicine‐refractory cases were treated with Kampo medicine. In Type 2, which is the combination of Kampo and Western medicines, there were various applications of Kampo medicine in clinical fields such as pain control, respiratory, cardiovascular, and psychiatric subspecialties. Furthermore, in Type 3, which is also the combination of Kampo and Western medicines, 7 of 12 presentations were related to the alleviation of the side effects of cancer therapy.Kampo monotherapy is most popularly reported at the Congress of JSOM in various fields of medicine, whereas the concurrent use of Kampo and Western medicines is also reported in a variety of clinical subspecialties. A new horizon of clinical significance for Kampo medicine will be opened with the Yasui Classification.","PeriodicalId":507365,"journal":{"name":"Traditional & Kampo Medicine","volume":"115 1-3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139861655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hajime Nakae, Hideomi Tsuchida, K. Satoh, Manabu Okuyama
{"title":"The pain‐relieving effect of jidabokuippo in bear‐related trauma","authors":"Hajime Nakae, Hideomi Tsuchida, K. Satoh, Manabu Okuyama","doi":"10.1002/tkm2.1397","DOIUrl":"https://doi.org/10.1002/tkm2.1397","url":null,"abstract":"","PeriodicalId":507365,"journal":{"name":"Traditional & Kampo Medicine","volume":"55 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139154066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Shaikh, Mohd Urooj, Uzma Viquar, G. Javed, M. H. Kazmi, G. M. Husain
According to classical Unani literature, the multicomponent traditional Unani formulation majoon‐e‐nisyan is used to treat amnesia and cognitive impairment. The purpose of the current study was to evaluate majoon‐e‐nisyan's effectiveness in improving cognitive function.Majoon‐e‐Nisyan was prepared as per traditional method. The cognitive function was evaluated using the passive avoidance test and the water maze experiment in mice. The effectiveness of the test drug was compared to that of the positive control drug, piracetam.Passive avoidance data recorded during the memory retention trial showed that transfer latency was significantly increased by majoon‐e‐nisyan at 1000 mg/kg bw (body weight) (p < 0.05) and at 1500 mg/kg bw (p < 0.001) as well as by the positive control (p < 0.001) compared to scopolamine control (negative control). Data of the water maze experiment showed a significant increase (p < 0.01) in time spent near the platform quadrant following treatment with the test drug at mid‐dose (1000 mg/kg bw) and high dose (1500 mg/kg bw) in comparison with vehicle control. A significant increase in time spent in the platform quadrant was also observed in the piracetam group (p < 0.01).The study indicated that majoon‐e‐nisyan had a beneficial effect on cognitive functions at tested dose levels of 1000 and 1500 mg/kg bw in both models. However, the dose of 500 mg/kg bw was ineffective. The current study was successful in demonstrating the effectiveness of majoon‐e‐nisyan using two validated mouse models. Our findings provide more evidence in favor of the concept of hot‐tempered medications used in traditional Unani medicine to treat dementia. This formulation may be used as an alternative to conventional dementia medications.
{"title":"Effect of Majoon‐e‐Nisyan (a traditional polyherbal Unani formulation) in animal models of learning and memory","authors":"M. Shaikh, Mohd Urooj, Uzma Viquar, G. Javed, M. H. Kazmi, G. M. Husain","doi":"10.1002/tkm2.1394","DOIUrl":"https://doi.org/10.1002/tkm2.1394","url":null,"abstract":"According to classical Unani literature, the multicomponent traditional Unani formulation majoon‐e‐nisyan is used to treat amnesia and cognitive impairment. The purpose of the current study was to evaluate majoon‐e‐nisyan's effectiveness in improving cognitive function.Majoon‐e‐Nisyan was prepared as per traditional method. The cognitive function was evaluated using the passive avoidance test and the water maze experiment in mice. The effectiveness of the test drug was compared to that of the positive control drug, piracetam.Passive avoidance data recorded during the memory retention trial showed that transfer latency was significantly increased by majoon‐e‐nisyan at 1000 mg/kg bw (body weight) (p < 0.05) and at 1500 mg/kg bw (p < 0.001) as well as by the positive control (p < 0.001) compared to scopolamine control (negative control). Data of the water maze experiment showed a significant increase (p < 0.01) in time spent near the platform quadrant following treatment with the test drug at mid‐dose (1000 mg/kg bw) and high dose (1500 mg/kg bw) in comparison with vehicle control. A significant increase in time spent in the platform quadrant was also observed in the piracetam group (p < 0.01).The study indicated that majoon‐e‐nisyan had a beneficial effect on cognitive functions at tested dose levels of 1000 and 1500 mg/kg bw in both models. However, the dose of 500 mg/kg bw was ineffective. The current study was successful in demonstrating the effectiveness of majoon‐e‐nisyan using two validated mouse models. Our findings provide more evidence in favor of the concept of hot‐tempered medications used in traditional Unani medicine to treat dementia. This formulation may be used as an alternative to conventional dementia medications.","PeriodicalId":507365,"journal":{"name":"Traditional & Kampo Medicine","volume":"190 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139206410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Kawashima, S. Kataoka, M. Hamada, Eri Nishikawa, Rieko Taniguchi, A. Narita, H. Muramatsu, N. Nishio, Yoshiyuki Takahashi
This study aimed to describe children developing late gastrointestinal (GI) complications after allogeneic hematopoietic stem cell transplantation (allo‐HSCT), focusing on Kampo medicine.At the Nagoya University Hospital Department of Pediatrics, 179 consecutive patients underwent allo‐HSCT over five years, of whom 167 achieved engraftment and survived at least 100 days post transplant and therefore were included in the study.Thirteen patients (7.8%) developed late GI symptoms. Among these, three had upper GI symptoms, three had lower GI symptoms, while seven had upper/lower GI symptoms. Total parenteral nutrition was administered in 10 (77%) patients for a median of 81 days (range: 20–303). Four (31%) had histologically proven graft‐versus‐host‐disease (GVHD), two (15%) had adverse drug reactions, and one (8%) had a viral infection. All three patients with lower GI symptoms responded to Kampo formulas' warming interior [TM1]. Two patients with upper GI symptoms had epigastric rigidity and responded to Aurantii Fructus Immaturus‐based formulas. One patient developed severe cachexia, which was successfully reversed with Kampo medicines. There were no adverse effects due to Kampo medicines.Late GI complications may be a burden on children after allo‐HSCT. Kampo medicines may provide a safe and promising therapy to resolve GI symptoms not otherwise specified.
{"title":"Late gastroenterological complications in children after allogeneic hematopoietic stem cell transplantation: A retrospective cohort study and a case series of children treated with Kampo medicines","authors":"N. Kawashima, S. Kataoka, M. Hamada, Eri Nishikawa, Rieko Taniguchi, A. Narita, H. Muramatsu, N. Nishio, Yoshiyuki Takahashi","doi":"10.1002/tkm2.1392","DOIUrl":"https://doi.org/10.1002/tkm2.1392","url":null,"abstract":"This study aimed to describe children developing late gastrointestinal (GI) complications after allogeneic hematopoietic stem cell transplantation (allo‐HSCT), focusing on Kampo medicine.At the Nagoya University Hospital Department of Pediatrics, 179 consecutive patients underwent allo‐HSCT over five years, of whom 167 achieved engraftment and survived at least 100 days post transplant and therefore were included in the study.Thirteen patients (7.8%) developed late GI symptoms. Among these, three had upper GI symptoms, three had lower GI symptoms, while seven had upper/lower GI symptoms. Total parenteral nutrition was administered in 10 (77%) patients for a median of 81 days (range: 20–303). Four (31%) had histologically proven graft‐versus‐host‐disease (GVHD), two (15%) had adverse drug reactions, and one (8%) had a viral infection. All three patients with lower GI symptoms responded to Kampo formulas' warming interior [TM1]. Two patients with upper GI symptoms had epigastric rigidity and responded to Aurantii Fructus Immaturus‐based formulas. One patient developed severe cachexia, which was successfully reversed with Kampo medicines. There were no adverse effects due to Kampo medicines.Late GI complications may be a burden on children after allo‐HSCT. Kampo medicines may provide a safe and promising therapy to resolve GI symptoms not otherwise specified.","PeriodicalId":507365,"journal":{"name":"Traditional & Kampo Medicine","volume":"22 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139256398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：